WO2011092720A3 - Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts and process for their preparation - Google Patents

Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts and process for their preparation Download PDF

Info

Publication number
WO2011092720A3
WO2011092720A3 PCT/IN2011/000066 IN2011000066W WO2011092720A3 WO 2011092720 A3 WO2011092720 A3 WO 2011092720A3 IN 2011000066 W IN2011000066 W IN 2011000066W WO 2011092720 A3 WO2011092720 A3 WO 2011092720A3
Authority
WO
WIPO (PCT)
Prior art keywords
prasugrel
pharmaceutical composition
pharmaceutically acceptable
acceptable salts
preparation
Prior art date
Application number
PCT/IN2011/000066
Other languages
French (fr)
Other versions
WO2011092720A2 (en
Inventor
Manne Satyanarayana Reddy
Srinivasan Thirumalai Rajan
Madhu Elevathingal Nicholas
Karamala Rama Subba Reddy
Original Assignee
Msn Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Limited filed Critical Msn Laboratories Limited
Publication of WO2011092720A2 publication Critical patent/WO2011092720A2/en
Publication of WO2011092720A3 publication Critical patent/WO2011092720A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition of prasugrel or its pharmaceutically acceptable salts, especially hydrochloride salts as well as process for their preparation are provided. The pharmaceutical composition comprises: a) prasugrel hydrochloride, b) a water insoluble dry binder, c) at least one diluent, d )at least one disintegrant and e) at least one lubricant. The pharmaceutical composition is optionally coated with a film. An improved process for preparing of prasugrel and its pharmaceutically acceptable salts, a process for purifying 5,6,7,7a-tetrahydro-4H-thieno[3,2-c]pyridine-2 -one hydrochloride compound, a process for preparing crystalline form-B2 of prasugrel hydrochloride and a process for preparing a-cyclopropylcarbonyl-2-fluorobenzyl bromide compound are provided.
PCT/IN2011/000066 2010-02-01 2011-01-31 Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts WO2011092720A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN244CH2010 2010-02-01
IN244/CHE/2010 2010-02-01

Publications (2)

Publication Number Publication Date
WO2011092720A2 WO2011092720A2 (en) 2011-08-04
WO2011092720A3 true WO2011092720A3 (en) 2011-09-22

Family

ID=44319930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000066 WO2011092720A2 (en) 2010-02-01 2011-01-31 Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts

Country Status (1)

Country Link
WO (1) WO2011092720A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565773B (en) * 2012-08-07 2017-12-05 广东东阳光药业有限公司 A kind of pharmaceutical composition of prasugrel hydrochloride
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
GR1009230B (en) 2016-10-12 2018-02-22 Φαρματεν Αβεε Pharmaceutical prasugrel besylate-containing formula
WO2024138216A2 (en) * 2022-12-23 2024-06-27 Case Western Reserve University Compositions and methods for treating and detecting cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298132A1 (en) * 2000-07-06 2003-04-02 Sankyo Company, Limited Hydropyridine derivative acid addition salts
WO2006135605A2 (en) * 2005-06-10 2006-12-21 Eli Lilly And Company Formulation of a thienopyridine platelet aggregation inhibitor
WO2009062044A2 (en) * 2007-11-09 2009-05-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel, and its salts and polymorphs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298132A1 (en) * 2000-07-06 2003-04-02 Sankyo Company, Limited Hydropyridine derivative acid addition salts
WO2006135605A2 (en) * 2005-06-10 2006-12-21 Eli Lilly And Company Formulation of a thienopyridine platelet aggregation inhibitor
WO2009062044A2 (en) * 2007-11-09 2009-05-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel, and its salts and polymorphs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JING, YAPING ET AL.: "Synthesis of the intermediate of prasugrel", JOURNAL OF GUANGDONG PHARMACEUTICAL COLLEGE, vol. 25, no. 3, June 2009 (2009-06-01), pages 272 - 274 *

Also Published As

Publication number Publication date
WO2011092720A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2012054110A3 (en) Compounds and methods for inhibiting phosphate transport
HRP20221304T1 (en) Combination comprising an mek inhibitor and a b-raf inhibitor
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
IL193951A (en) Bridged compound with central pyrrolidine units, an intermediate compound for the preparation of the bridged compound, a process for producing the bridged compound, use of the bridged compound for the manufacture of a medicament, a pharmaceutical composition, a method of preparing a pharmaceutical composition and a method for the preparation of a pharmaceutically acceptable salt of a non-salt compound
WO2009054479A1 (en) Spiro-ring compound and use thereof for medical purposes
WO2008135791A8 (en) Imidazoquinolines with immuno-modulating properties
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
WO2011012816A3 (en) Pharmaceutical formulation
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
WO2008120725A1 (en) Novel pyrrolinone derivative and medicinal composition containing the same
WO2011092719A3 (en) Process for preparing 1 -phenyl-3 -dimethylaminopropane derivatives
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
WO2010132765A3 (en) Antibacterial aminoglycoside analogs
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
WO2009140341A3 (en) Atorvastatin compositions
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
IL217557A (en) 1-oxa-4,9-diazaspiro[5.5]undec-4-yl(1,3-thiazole-4-yl)methanone derivatives and salts thereof
WO2014207664A3 (en) Stable pharmaceutical composition of asenapine
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2011092720A3 (en) Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts and process for their preparation
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11736719

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11736719

Country of ref document: EP

Kind code of ref document: A2